STROSUTRO BIOPHARMA, INC.vs its industry peers
A metric-by-metric comparison of SUTRO BIOPHARMA, INC. against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STROThis | $151M#1 | — | — | 1.5x#1 | 65.2%#1 | 15.9%#1 | -154.5%#1 | — | — | — | -20.8%#1 | — |
| AVXL | $110M#2 | — | 1.0x#2 | — | — | -7.8%#2 | — | -41.2%#1 | — | — | — | — |
| VYGR | $106M#3 | — | 0.7x#1 | 2.6x#2 | -49.5%#2 | -84.2%#3 | -326.6%#2 | -77.6%#2 | — | — | -62.0%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-11-01.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice